A recent study compared two dosages of ifinatamab deruxtecan among patients with extensive-stage small cell lung cancer.

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Last month, Daiichi Sankyo and MSD announced the dosing of the first participant in the Phase III IDeate-Lung02 trial of ifinatamab deruxtecan (I-DXd) in people with relapsed small cell lung cancer ...

Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...

TOKYO, Japan & BASKING RIDGE, NJ, USA I 15, 2024 I Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest ...